Both the mirror and manufacturer print 1.72 m2 for renal PK; the manufacturer also uses 1.73 m2 for trial exclusion. This is not an isolated mirror transcription error.
Before applying: Do not normalize the unusual units or infer a severe-renal regimen. Check the exact product, interactions and full labeling.
Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
Belumosudil - REZUROCK oral tablets
Product / population
Age 12 years and older; chronic GVHD after at least two prior systemic treatments.
Renal measure
eGFR: PK paragraph prints mL/min/1.72 m2; trial exclusion prints 1.73 m2.
Renal guidance and important limits
Limits that apply to these rows
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
REZUROCK - renal evidence, not a dose ladder
Source renal population
Source-specific instruction
eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2)
No clinically significant pharmacokinetic difference reported.
Pre-existing severe renal impairment
Not studied; weigh risks and benefits before starting.
Read the retained text before reformatting
REZUROCK - renal evidence, not a dose ladder
Source renal population
Source-specific instruction
eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2)
No clinically significant pharmacokinetic difference reported.
Pre-existing severe renal impairment
Not studied; weigh risks and benefits before starting.
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
Source revision: 01/2026 | Retrieved: 2026-09-10. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
source scope and renal guidance
Before use: Belumosudil - REZUROCK oral tablets
Both the mirror and manufacturer print 1.72 m2 for renal PK; the manufacturer also uses 1.73 m2 for trial exclusion. This is not an isolated mirror transcription error.
How to use this: Do not normalize the unusual units or infer a severe-renal regimen. Check the exact product, interactions and full labeling.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
Belumosudil - REZUROCK oral tablets
Age 12 years and older; chronic GVHD after at least two prior systemic treatments.
Method: eGFR: PK paragraph prints mL/min/1.72 m2; trial exclusion prints 1.73 m2.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Sanofi / manufacturer prescribing information · Age 12 years and older; chronic GVHD after at least two prior systemic treatments.
Renal method: eGFR: PK paragraph prints mL/min/1.72 m2; trial exclusion prints 1.73 m2. Source date: 01/2026 Retrieved: 2026-09-10
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding
Do not normalize the unusual units or infer a severe-renal regimen. Check the exact product, interactions and full labeling.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
REZUROCK - renal evidence, not a dose ladder
Source renal population
Source-specific instruction
eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2)
No clinically significant pharmacokinetic difference reported.
Pre-existing severe renal impairment
Not studied; weigh risks and benefits before starting.
Read the retained text before reformatting
REZUROCK - renal evidence, not a dose ladder
Source renal population
Source-specific instruction
eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2)
No clinically significant pharmacokinetic difference reported.
Pre-existing severe renal impairment
Not studied; weigh risks and benefits before starting.
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
RDM64-official-belumosudil-rezurock-a7ba1181bc-C1 · Source locator: Sections 2.1-2.3, 8.6, 12.3, 14.1; manufacturer PDF pages 1, 3 and 4 inspected.
Source-specific limits
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding
Do not normalize the unusual units or infer a severe-renal regimen. Check the exact product, interactions and full labeling.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
REZUROCK - renal evidence, not a dose ladder
Source renal population
Source-specific instruction
eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2)
No clinically significant pharmacokinetic difference reported.
Pre-existing severe renal impairment
Not studied; weigh risks and benefits before starting.
Read the retained text before reformatting
REZUROCK - renal evidence, not a dose ladder
Source renal population
Source-specific instruction
eGFR >=60 to <90 and >=30 to <60 (printed per 1.72 m2)
No clinically significant pharmacokinetic difference reported.
Pre-existing severe renal impairment
Not studied; weigh risks and benefits before starting.
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
RDM64-rxlist-belumosudil-rezurock-f36e47a224-C1 · Source locator: Sections 2.1-2.3, 8.6, 12.3, 14.1; manufacturer PDF pages 1, 3 and 4 inspected.
Source-specific limits
The usual dose is 200 mg orally once daily with food. No severe-renal dose or dialysis supplement is established here.
The source prints 1.72 m2 in its PK paragraph. Do not silently substitute another renal measure. Interaction, hepatic and embryo-fetal safeguards still apply; monitor bilirubin, AST and ALT at least monthly.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.